Global and Regional Biologics
Global and Regional Biologics

Biologics Comprehensive Study by Type (Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cellular-based Biologics, Gene-based Biologics, Other), Application (Cancer, Infectious Diseases, Autoimmune Diseases, Other), Drug Type (Branded Drugs, Generic Drugs), End-User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2027

Biologics Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Apr 2022 Edition 220 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Biologics Market Overview:
A biologic drug (biologic) is a chemical derived from or containing components of living organisms. For the manufacture of new biologics, new technologies and novel therapies are emerging, indicating that the global biologics market has a bright future. Biologics are widely utilized to treat, diagnose, and cure a wide range of ailments, including cancer, chronic renal disease, autoimmune disorders, and infectious infections. Patenting, testing, safety, efficacy, and marketing are only a few of the laws and regulations that apply to biologics. Biotechnological approaches and other cutting-edge technologies are used to isolate biologics products from natural sources such as humans, animals, and microorganisms.

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Historical Period2017-2021
UnitValue (USD Million)
Key Companies ProfiledMerck & Co., Inc. (United States), AbbVie Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Johnson & Johnson (United States), Pfizer Inc. (United States), AstraZeneca (United Kingdom), ABLbio (South Korea), Adimmune (Taiwan), Helius (India) and Innovent Biologics (China)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Growth Drivers
  • The rise in the Robust Pipeline of Biologics
  • Chronic Disease Incidence and Diagnosis are on the Rise across the Globe
  • Increased Global Adoption of Novel Biologics Drugs and Therapies

Roadblocks
  • Clinical Trials with High Strictness and Low Turnover
  • Biologics Are Costly and Never Get Refunded

Opportunities
  • Increases Funding In Developing Country
  • Increasing Drug Manufactures In Developing Country

Challenges
  • Strict Government Regulation
  • Issues with Drug Molecule Structure Complexity in Biologics


Competitive Landscape:
There are several main participants in the biologics market, which is moderately competitive. Certain strategic activities, such as mergers, new product launches, acquisitions, and collaborations, are being implemented by the firms to help them increase their market positions. Due to the high cost of biologics, these businesses have made significant capital investments in biologics research and development.
Some of the key players profiled in the report are Merck & Co., Inc. (United States), AbbVie Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Johnson & Johnson (United States), Pfizer Inc. (United States), AstraZeneca (United Kingdom), ABLbio (South Korea), Adimmune (Taiwan), Helius (India) and Innovent Biologics (China). Additionally, following companies can also be profiled that are part of our coverage like Bio-Thera (China), Hisun Pharma (China) and 3SBio (China). Analyst at AMA Research see United States Players to retain maximum share of Global Biologics market by 2027. Considering Market by Drug Type, the sub-segment i.e. Branded Drugs will boost the Biologics market. Considering Market by End-User, the sub-segment i.e. Hospital Pharmacies will boost the Biologics market.

In April 2021, Novartis AG (Sandoz) and Bio-Thera Solutions (China) have agreed to commercialize BAT1706 (Bio-Thera Solutions' proposed bevacizumab biosimilar) in the United States, Europe, Canada, and other international markets. and In Aug 2020, Semglee has been launched in the United States by Biocon Biologics India, a fully integrated biosimilar firm and a subsidiary of Biocon Ltd, and Mylan NV (insulin glargine injection). As a result, all of these characteristics have been discovered to help the region's total market growth.

What Can be Explored with the Biologics Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Biologics Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Biologics
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Biologics market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Biologics market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Industry Association, Downstream Vendors, Marketing & Consulting firms, Venture Capitalists, Government & Regulatory Bodies and Investors.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. What is the growth rate predicted for the Global Biologics Market?
The Biologics market is expected to see a CAGR of % during projected year 2021 to 2027.

2. Who are the top performing companies in Biologics Market?
Top performing companies in the Global Biologics market are Merck & Co., Inc. (United States), AbbVie Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Johnson & Johnson (United States), Pfizer Inc. (United States), AstraZeneca (United Kingdom), ABLbio (South Korea), Adimmune (Taiwan), Helius (India) and Innovent Biologics (China), to name a few.

3. What trending factors would impact Biologics Market growth most?
"FDA Regulations Revised to Make Biologics Drug Development Easier " is seen as one of major influencing trends for Biologics Market during projected period 2021-2027.

Report Objectives / Segmentation Covered
By Type
  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Hormones/Proteins
  • Cellular-based Biologics
  • Gene-based Biologics
  • Other
By Application
  • Cancer
  • Infectious Diseases
  • Autoimmune Diseases
  • Other
By Drug Type
  • Branded Drugs
  • Generic Drugs

By End-User
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The rise in the Robust Pipeline of Biologics
      • 3.2.2. Chronic Disease Incidence and Diagnosis are on the Rise across the Globe
      • 3.2.3. Increased Global Adoption of Novel Biologics Drugs and Therapies
    • 3.3. Market Challenges
      • 3.3.1. Strict Government Regulation
      • 3.3.2. Issues with Drug Molecule Structure Complexity in Biologics
    • 3.4. Market Trends
      • 3.4.1. FDA Regulations Revised to Make Biologics Drug Development Easier
      • 3.4.2. Higher Profit Margins for Biologics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Biologics, by Type, Application, Drug Type, End-User and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Biologics (Value)
      • 5.2.1. Global Biologics by: Type (Value)
        • 5.2.1.1. Monoclonal Antibodies
        • 5.2.1.2. Vaccines
        • 5.2.1.3. Recombinant Hormones/Proteins
        • 5.2.1.4. Cellular-based Biologics
        • 5.2.1.5. Gene-based Biologics
        • 5.2.1.6. Other
      • 5.2.2. Global Biologics by: Application (Value)
        • 5.2.2.1. Cancer
        • 5.2.2.2. Infectious Diseases
        • 5.2.2.3. Autoimmune Diseases
        • 5.2.2.4. Other
      • 5.2.3. Global Biologics by: Drug Type (Value)
        • 5.2.3.1. Branded Drugs
        • 5.2.3.2. Generic Drugs
      • 5.2.4. Global Biologics by: End-User (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online Pharmacies
      • 5.2.5. Global Biologics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Biologics (Price)
      • 5.3.1. Global Biologics by: Type (Price)
  • 6. Biologics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co., Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AbbVie Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AstraZeneca (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ABLbio (South Korea)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Adimmune (Taiwan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Helius (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Innovent Biologics (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Biologics Sale, by Type, Application, Drug Type, End-User and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Biologics (Value)
      • 7.2.1. Global Biologics by: Type (Value)
        • 7.2.1.1. Monoclonal Antibodies
        • 7.2.1.2. Vaccines
        • 7.2.1.3. Recombinant Hormones/Proteins
        • 7.2.1.4. Cellular-based Biologics
        • 7.2.1.5. Gene-based Biologics
        • 7.2.1.6. Other
      • 7.2.2. Global Biologics by: Application (Value)
        • 7.2.2.1. Cancer
        • 7.2.2.2. Infectious Diseases
        • 7.2.2.3. Autoimmune Diseases
        • 7.2.2.4. Other
      • 7.2.3. Global Biologics by: Drug Type (Value)
        • 7.2.3.1. Branded Drugs
        • 7.2.3.2. Generic Drugs
      • 7.2.4. Global Biologics by: End-User (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online Pharmacies
      • 7.2.5. Global Biologics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Biologics (Price)
      • 7.3.1. Global Biologics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Biologics: by Type(USD Million)
  • Table 2. Biologics Monoclonal Antibodies , by Region USD Million (2016-2021)
  • Table 3. Biologics Vaccines , by Region USD Million (2016-2021)
  • Table 4. Biologics Recombinant Hormones/Proteins , by Region USD Million (2016-2021)
  • Table 5. Biologics Cellular-based Biologics , by Region USD Million (2016-2021)
  • Table 6. Biologics Gene-based Biologics , by Region USD Million (2016-2021)
  • Table 7. Biologics Other , by Region USD Million (2016-2021)
  • Table 8. Biologics: by Application(USD Million)
  • Table 9. Biologics Cancer , by Region USD Million (2016-2021)
  • Table 10. Biologics Infectious Diseases , by Region USD Million (2016-2021)
  • Table 11. Biologics Autoimmune Diseases , by Region USD Million (2016-2021)
  • Table 12. Biologics Other , by Region USD Million (2016-2021)
  • Table 13. Biologics: by Drug Type(USD Million)
  • Table 14. Biologics Branded Drugs , by Region USD Million (2016-2021)
  • Table 15. Biologics Generic Drugs , by Region USD Million (2016-2021)
  • Table 16. Biologics: by End-User(USD Million)
  • Table 17. Biologics Hospital Pharmacies , by Region USD Million (2016-2021)
  • Table 18. Biologics Retail Pharmacies , by Region USD Million (2016-2021)
  • Table 19. Biologics Online Pharmacies , by Region USD Million (2016-2021)
  • Table 20. South America Biologics, by Country USD Million (2016-2021)
  • Table 21. South America Biologics, by Type USD Million (2016-2021)
  • Table 22. South America Biologics, by Application USD Million (2016-2021)
  • Table 23. South America Biologics, by Drug Type USD Million (2016-2021)
  • Table 24. South America Biologics, by End-User USD Million (2016-2021)
  • Table 25. Brazil Biologics, by Type USD Million (2016-2021)
  • Table 26. Brazil Biologics, by Application USD Million (2016-2021)
  • Table 27. Brazil Biologics, by Drug Type USD Million (2016-2021)
  • Table 28. Brazil Biologics, by End-User USD Million (2016-2021)
  • Table 29. Argentina Biologics, by Type USD Million (2016-2021)
  • Table 30. Argentina Biologics, by Application USD Million (2016-2021)
  • Table 31. Argentina Biologics, by Drug Type USD Million (2016-2021)
  • Table 32. Argentina Biologics, by End-User USD Million (2016-2021)
  • Table 33. Rest of South America Biologics, by Type USD Million (2016-2021)
  • Table 34. Rest of South America Biologics, by Application USD Million (2016-2021)
  • Table 35. Rest of South America Biologics, by Drug Type USD Million (2016-2021)
  • Table 36. Rest of South America Biologics, by End-User USD Million (2016-2021)
  • Table 37. Asia Pacific Biologics, by Country USD Million (2016-2021)
  • Table 38. Asia Pacific Biologics, by Type USD Million (2016-2021)
  • Table 39. Asia Pacific Biologics, by Application USD Million (2016-2021)
  • Table 40. Asia Pacific Biologics, by Drug Type USD Million (2016-2021)
  • Table 41. Asia Pacific Biologics, by End-User USD Million (2016-2021)
  • Table 42. China Biologics, by Type USD Million (2016-2021)
  • Table 43. China Biologics, by Application USD Million (2016-2021)
  • Table 44. China Biologics, by Drug Type USD Million (2016-2021)
  • Table 45. China Biologics, by End-User USD Million (2016-2021)
  • Table 46. Japan Biologics, by Type USD Million (2016-2021)
  • Table 47. Japan Biologics, by Application USD Million (2016-2021)
  • Table 48. Japan Biologics, by Drug Type USD Million (2016-2021)
  • Table 49. Japan Biologics, by End-User USD Million (2016-2021)
  • Table 50. India Biologics, by Type USD Million (2016-2021)
  • Table 51. India Biologics, by Application USD Million (2016-2021)
  • Table 52. India Biologics, by Drug Type USD Million (2016-2021)
  • Table 53. India Biologics, by End-User USD Million (2016-2021)
  • Table 54. South Korea Biologics, by Type USD Million (2016-2021)
  • Table 55. South Korea Biologics, by Application USD Million (2016-2021)
  • Table 56. South Korea Biologics, by Drug Type USD Million (2016-2021)
  • Table 57. South Korea Biologics, by End-User USD Million (2016-2021)
  • Table 58. Taiwan Biologics, by Type USD Million (2016-2021)
  • Table 59. Taiwan Biologics, by Application USD Million (2016-2021)
  • Table 60. Taiwan Biologics, by Drug Type USD Million (2016-2021)
  • Table 61. Taiwan Biologics, by End-User USD Million (2016-2021)
  • Table 62. Australia Biologics, by Type USD Million (2016-2021)
  • Table 63. Australia Biologics, by Application USD Million (2016-2021)
  • Table 64. Australia Biologics, by Drug Type USD Million (2016-2021)
  • Table 65. Australia Biologics, by End-User USD Million (2016-2021)
  • Table 66. Rest of Asia-Pacific Biologics, by Type USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Biologics, by Application USD Million (2016-2021)
  • Table 68. Rest of Asia-Pacific Biologics, by Drug Type USD Million (2016-2021)
  • Table 69. Rest of Asia-Pacific Biologics, by End-User USD Million (2016-2021)
  • Table 70. Europe Biologics, by Country USD Million (2016-2021)
  • Table 71. Europe Biologics, by Type USD Million (2016-2021)
  • Table 72. Europe Biologics, by Application USD Million (2016-2021)
  • Table 73. Europe Biologics, by Drug Type USD Million (2016-2021)
  • Table 74. Europe Biologics, by End-User USD Million (2016-2021)
  • Table 75. Germany Biologics, by Type USD Million (2016-2021)
  • Table 76. Germany Biologics, by Application USD Million (2016-2021)
  • Table 77. Germany Biologics, by Drug Type USD Million (2016-2021)
  • Table 78. Germany Biologics, by End-User USD Million (2016-2021)
  • Table 79. France Biologics, by Type USD Million (2016-2021)
  • Table 80. France Biologics, by Application USD Million (2016-2021)
  • Table 81. France Biologics, by Drug Type USD Million (2016-2021)
  • Table 82. France Biologics, by End-User USD Million (2016-2021)
  • Table 83. Italy Biologics, by Type USD Million (2016-2021)
  • Table 84. Italy Biologics, by Application USD Million (2016-2021)
  • Table 85. Italy Biologics, by Drug Type USD Million (2016-2021)
  • Table 86. Italy Biologics, by End-User USD Million (2016-2021)
  • Table 87. United Kingdom Biologics, by Type USD Million (2016-2021)
  • Table 88. United Kingdom Biologics, by Application USD Million (2016-2021)
  • Table 89. United Kingdom Biologics, by Drug Type USD Million (2016-2021)
  • Table 90. United Kingdom Biologics, by End-User USD Million (2016-2021)
  • Table 91. Netherlands Biologics, by Type USD Million (2016-2021)
  • Table 92. Netherlands Biologics, by Application USD Million (2016-2021)
  • Table 93. Netherlands Biologics, by Drug Type USD Million (2016-2021)
  • Table 94. Netherlands Biologics, by End-User USD Million (2016-2021)
  • Table 95. Rest of Europe Biologics, by Type USD Million (2016-2021)
  • Table 96. Rest of Europe Biologics, by Application USD Million (2016-2021)
  • Table 97. Rest of Europe Biologics, by Drug Type USD Million (2016-2021)
  • Table 98. Rest of Europe Biologics, by End-User USD Million (2016-2021)
  • Table 99. MEA Biologics, by Country USD Million (2016-2021)
  • Table 100. MEA Biologics, by Type USD Million (2016-2021)
  • Table 101. MEA Biologics, by Application USD Million (2016-2021)
  • Table 102. MEA Biologics, by Drug Type USD Million (2016-2021)
  • Table 103. MEA Biologics, by End-User USD Million (2016-2021)
  • Table 104. Middle East Biologics, by Type USD Million (2016-2021)
  • Table 105. Middle East Biologics, by Application USD Million (2016-2021)
  • Table 106. Middle East Biologics, by Drug Type USD Million (2016-2021)
  • Table 107. Middle East Biologics, by End-User USD Million (2016-2021)
  • Table 108. Africa Biologics, by Type USD Million (2016-2021)
  • Table 109. Africa Biologics, by Application USD Million (2016-2021)
  • Table 110. Africa Biologics, by Drug Type USD Million (2016-2021)
  • Table 111. Africa Biologics, by End-User USD Million (2016-2021)
  • Table 112. North America Biologics, by Country USD Million (2016-2021)
  • Table 113. North America Biologics, by Type USD Million (2016-2021)
  • Table 114. North America Biologics, by Application USD Million (2016-2021)
  • Table 115. North America Biologics, by Drug Type USD Million (2016-2021)
  • Table 116. North America Biologics, by End-User USD Million (2016-2021)
  • Table 117. United States Biologics, by Type USD Million (2016-2021)
  • Table 118. United States Biologics, by Application USD Million (2016-2021)
  • Table 119. United States Biologics, by Drug Type USD Million (2016-2021)
  • Table 120. United States Biologics, by End-User USD Million (2016-2021)
  • Table 121. Canada Biologics, by Type USD Million (2016-2021)
  • Table 122. Canada Biologics, by Application USD Million (2016-2021)
  • Table 123. Canada Biologics, by Drug Type USD Million (2016-2021)
  • Table 124. Canada Biologics, by End-User USD Million (2016-2021)
  • Table 125. Mexico Biologics, by Type USD Million (2016-2021)
  • Table 126. Mexico Biologics, by Application USD Million (2016-2021)
  • Table 127. Mexico Biologics, by Drug Type USD Million (2016-2021)
  • Table 128. Mexico Biologics, by End-User USD Million (2016-2021)
  • Table 129. Biologics: by Type(USD/Units)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Biologics: by Type(USD Million)
  • Table 141. Biologics Monoclonal Antibodies , by Region USD Million (2022-2027)
  • Table 142. Biologics Vaccines , by Region USD Million (2022-2027)
  • Table 143. Biologics Recombinant Hormones/Proteins , by Region USD Million (2022-2027)
  • Table 144. Biologics Cellular-based Biologics , by Region USD Million (2022-2027)
  • Table 145. Biologics Gene-based Biologics , by Region USD Million (2022-2027)
  • Table 146. Biologics Other , by Region USD Million (2022-2027)
  • Table 147. Biologics: by Application(USD Million)
  • Table 148. Biologics Cancer , by Region USD Million (2022-2027)
  • Table 149. Biologics Infectious Diseases , by Region USD Million (2022-2027)
  • Table 150. Biologics Autoimmune Diseases , by Region USD Million (2022-2027)
  • Table 151. Biologics Other , by Region USD Million (2022-2027)
  • Table 152. Biologics: by Drug Type(USD Million)
  • Table 153. Biologics Branded Drugs , by Region USD Million (2022-2027)
  • Table 154. Biologics Generic Drugs , by Region USD Million (2022-2027)
  • Table 155. Biologics: by End-User(USD Million)
  • Table 156. Biologics Hospital Pharmacies , by Region USD Million (2022-2027)
  • Table 157. Biologics Retail Pharmacies , by Region USD Million (2022-2027)
  • Table 158. Biologics Online Pharmacies , by Region USD Million (2022-2027)
  • Table 159. South America Biologics, by Country USD Million (2022-2027)
  • Table 160. South America Biologics, by Type USD Million (2022-2027)
  • Table 161. South America Biologics, by Application USD Million (2022-2027)
  • Table 162. South America Biologics, by Drug Type USD Million (2022-2027)
  • Table 163. South America Biologics, by End-User USD Million (2022-2027)
  • Table 164. Brazil Biologics, by Type USD Million (2022-2027)
  • Table 165. Brazil Biologics, by Application USD Million (2022-2027)
  • Table 166. Brazil Biologics, by Drug Type USD Million (2022-2027)
  • Table 167. Brazil Biologics, by End-User USD Million (2022-2027)
  • Table 168. Argentina Biologics, by Type USD Million (2022-2027)
  • Table 169. Argentina Biologics, by Application USD Million (2022-2027)
  • Table 170. Argentina Biologics, by Drug Type USD Million (2022-2027)
  • Table 171. Argentina Biologics, by End-User USD Million (2022-2027)
  • Table 172. Rest of South America Biologics, by Type USD Million (2022-2027)
  • Table 173. Rest of South America Biologics, by Application USD Million (2022-2027)
  • Table 174. Rest of South America Biologics, by Drug Type USD Million (2022-2027)
  • Table 175. Rest of South America Biologics, by End-User USD Million (2022-2027)
  • Table 176. Asia Pacific Biologics, by Country USD Million (2022-2027)
  • Table 177. Asia Pacific Biologics, by Type USD Million (2022-2027)
  • Table 178. Asia Pacific Biologics, by Application USD Million (2022-2027)
  • Table 179. Asia Pacific Biologics, by Drug Type USD Million (2022-2027)
  • Table 180. Asia Pacific Biologics, by End-User USD Million (2022-2027)
  • Table 181. China Biologics, by Type USD Million (2022-2027)
  • Table 182. China Biologics, by Application USD Million (2022-2027)
  • Table 183. China Biologics, by Drug Type USD Million (2022-2027)
  • Table 184. China Biologics, by End-User USD Million (2022-2027)
  • Table 185. Japan Biologics, by Type USD Million (2022-2027)
  • Table 186. Japan Biologics, by Application USD Million (2022-2027)
  • Table 187. Japan Biologics, by Drug Type USD Million (2022-2027)
  • Table 188. Japan Biologics, by End-User USD Million (2022-2027)
  • Table 189. India Biologics, by Type USD Million (2022-2027)
  • Table 190. India Biologics, by Application USD Million (2022-2027)
  • Table 191. India Biologics, by Drug Type USD Million (2022-2027)
  • Table 192. India Biologics, by End-User USD Million (2022-2027)
  • Table 193. South Korea Biologics, by Type USD Million (2022-2027)
  • Table 194. South Korea Biologics, by Application USD Million (2022-2027)
  • Table 195. South Korea Biologics, by Drug Type USD Million (2022-2027)
  • Table 196. South Korea Biologics, by End-User USD Million (2022-2027)
  • Table 197. Taiwan Biologics, by Type USD Million (2022-2027)
  • Table 198. Taiwan Biologics, by Application USD Million (2022-2027)
  • Table 199. Taiwan Biologics, by Drug Type USD Million (2022-2027)
  • Table 200. Taiwan Biologics, by End-User USD Million (2022-2027)
  • Table 201. Australia Biologics, by Type USD Million (2022-2027)
  • Table 202. Australia Biologics, by Application USD Million (2022-2027)
  • Table 203. Australia Biologics, by Drug Type USD Million (2022-2027)
  • Table 204. Australia Biologics, by End-User USD Million (2022-2027)
  • Table 205. Rest of Asia-Pacific Biologics, by Type USD Million (2022-2027)
  • Table 206. Rest of Asia-Pacific Biologics, by Application USD Million (2022-2027)
  • Table 207. Rest of Asia-Pacific Biologics, by Drug Type USD Million (2022-2027)
  • Table 208. Rest of Asia-Pacific Biologics, by End-User USD Million (2022-2027)
  • Table 209. Europe Biologics, by Country USD Million (2022-2027)
  • Table 210. Europe Biologics, by Type USD Million (2022-2027)
  • Table 211. Europe Biologics, by Application USD Million (2022-2027)
  • Table 212. Europe Biologics, by Drug Type USD Million (2022-2027)
  • Table 213. Europe Biologics, by End-User USD Million (2022-2027)
  • Table 214. Germany Biologics, by Type USD Million (2022-2027)
  • Table 215. Germany Biologics, by Application USD Million (2022-2027)
  • Table 216. Germany Biologics, by Drug Type USD Million (2022-2027)
  • Table 217. Germany Biologics, by End-User USD Million (2022-2027)
  • Table 218. France Biologics, by Type USD Million (2022-2027)
  • Table 219. France Biologics, by Application USD Million (2022-2027)
  • Table 220. France Biologics, by Drug Type USD Million (2022-2027)
  • Table 221. France Biologics, by End-User USD Million (2022-2027)
  • Table 222. Italy Biologics, by Type USD Million (2022-2027)
  • Table 223. Italy Biologics, by Application USD Million (2022-2027)
  • Table 224. Italy Biologics, by Drug Type USD Million (2022-2027)
  • Table 225. Italy Biologics, by End-User USD Million (2022-2027)
  • Table 226. United Kingdom Biologics, by Type USD Million (2022-2027)
  • Table 227. United Kingdom Biologics, by Application USD Million (2022-2027)
  • Table 228. United Kingdom Biologics, by Drug Type USD Million (2022-2027)
  • Table 229. United Kingdom Biologics, by End-User USD Million (2022-2027)
  • Table 230. Netherlands Biologics, by Type USD Million (2022-2027)
  • Table 231. Netherlands Biologics, by Application USD Million (2022-2027)
  • Table 232. Netherlands Biologics, by Drug Type USD Million (2022-2027)
  • Table 233. Netherlands Biologics, by End-User USD Million (2022-2027)
  • Table 234. Rest of Europe Biologics, by Type USD Million (2022-2027)
  • Table 235. Rest of Europe Biologics, by Application USD Million (2022-2027)
  • Table 236. Rest of Europe Biologics, by Drug Type USD Million (2022-2027)
  • Table 237. Rest of Europe Biologics, by End-User USD Million (2022-2027)
  • Table 238. MEA Biologics, by Country USD Million (2022-2027)
  • Table 239. MEA Biologics, by Type USD Million (2022-2027)
  • Table 240. MEA Biologics, by Application USD Million (2022-2027)
  • Table 241. MEA Biologics, by Drug Type USD Million (2022-2027)
  • Table 242. MEA Biologics, by End-User USD Million (2022-2027)
  • Table 243. Middle East Biologics, by Type USD Million (2022-2027)
  • Table 244. Middle East Biologics, by Application USD Million (2022-2027)
  • Table 245. Middle East Biologics, by Drug Type USD Million (2022-2027)
  • Table 246. Middle East Biologics, by End-User USD Million (2022-2027)
  • Table 247. Africa Biologics, by Type USD Million (2022-2027)
  • Table 248. Africa Biologics, by Application USD Million (2022-2027)
  • Table 249. Africa Biologics, by Drug Type USD Million (2022-2027)
  • Table 250. Africa Biologics, by End-User USD Million (2022-2027)
  • Table 251. North America Biologics, by Country USD Million (2022-2027)
  • Table 252. North America Biologics, by Type USD Million (2022-2027)
  • Table 253. North America Biologics, by Application USD Million (2022-2027)
  • Table 254. North America Biologics, by Drug Type USD Million (2022-2027)
  • Table 255. North America Biologics, by End-User USD Million (2022-2027)
  • Table 256. United States Biologics, by Type USD Million (2022-2027)
  • Table 257. United States Biologics, by Application USD Million (2022-2027)
  • Table 258. United States Biologics, by Drug Type USD Million (2022-2027)
  • Table 259. United States Biologics, by End-User USD Million (2022-2027)
  • Table 260. Canada Biologics, by Type USD Million (2022-2027)
  • Table 261. Canada Biologics, by Application USD Million (2022-2027)
  • Table 262. Canada Biologics, by Drug Type USD Million (2022-2027)
  • Table 263. Canada Biologics, by End-User USD Million (2022-2027)
  • Table 264. Mexico Biologics, by Type USD Million (2022-2027)
  • Table 265. Mexico Biologics, by Application USD Million (2022-2027)
  • Table 266. Mexico Biologics, by Drug Type USD Million (2022-2027)
  • Table 267. Mexico Biologics, by End-User USD Million (2022-2027)
  • Table 268. Biologics: by Type(USD/Units)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Biologics: by Type USD Million (2016-2021)
  • Figure 5. Global Biologics: by Application USD Million (2016-2021)
  • Figure 6. Global Biologics: by Drug Type USD Million (2016-2021)
  • Figure 7. Global Biologics: by End-User USD Million (2016-2021)
  • Figure 8. South America Biologics Share (%), by Country
  • Figure 9. Asia Pacific Biologics Share (%), by Country
  • Figure 10. Europe Biologics Share (%), by Country
  • Figure 11. MEA Biologics Share (%), by Country
  • Figure 12. North America Biologics Share (%), by Country
  • Figure 13. Global Biologics: by Type USD/Units (2016-2021)
  • Figure 14. Global Biologics share by Players 2021 (%)
  • Figure 15. Global Biologics share by Players (Top 3) 2021(%)
  • Figure 16. Global Biologics share by Players (Top 5) 2021(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Merck & Co., Inc. (United States) Revenue: by Geography 2021
  • Figure 20. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. AbbVie Inc. (United States) Revenue: by Geography 2021
  • Figure 22. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2021
  • Figure 24. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 25. Johnson & Johnson (United States) Revenue: by Geography 2021
  • Figure 26. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer Inc. (United States) Revenue: by Geography 2021
  • Figure 28. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. AstraZeneca (United Kingdom) Revenue: by Geography 2021
  • Figure 30. ABLbio (South Korea) Revenue, Net Income and Gross profit
  • Figure 31. ABLbio (South Korea) Revenue: by Geography 2021
  • Figure 32. Adimmune (Taiwan) Revenue, Net Income and Gross profit
  • Figure 33. Adimmune (Taiwan) Revenue: by Geography 2021
  • Figure 34. Helius (India) Revenue, Net Income and Gross profit
  • Figure 35. Helius (India) Revenue: by Geography 2021
  • Figure 36. Innovent Biologics (China) Revenue, Net Income and Gross profit
  • Figure 37. Innovent Biologics (China) Revenue: by Geography 2021
  • Figure 38. Global Biologics: by Type USD Million (2022-2027)
  • Figure 39. Global Biologics: by Application USD Million (2022-2027)
  • Figure 40. Global Biologics: by Drug Type USD Million (2022-2027)
  • Figure 41. Global Biologics: by End-User USD Million (2022-2027)
  • Figure 42. South America Biologics Share (%), by Country
  • Figure 43. Asia Pacific Biologics Share (%), by Country
  • Figure 44. Europe Biologics Share (%), by Country
  • Figure 45. MEA Biologics Share (%), by Country
  • Figure 46. North America Biologics Share (%), by Country
  • Figure 47. Global Biologics: by Type USD/Units (2022-2027)
Some of the key companies/manufacturers profiled in the report
  • Merck & Co., Inc. (United States)
  • AbbVie Inc. (United States)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Johnson & Johnson (United States)
  • Pfizer Inc. (United States)
  • AstraZeneca (United Kingdom)
  • ABLbio (South Korea)
  • Adimmune (Taiwan)
  • Helius (India)
  • Innovent Biologics (China)
Additional players considered in the study are as follows:
Bio-Thera (China) , Hisun Pharma (China) , 3SBio (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation